Immunocore Holdings plc ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $430.8M+38.9% YoYTTM through 30 Jun 2026
Net Income -$18.1MTTM through 30 Jun 2026
Free Cash Flow -$41.2MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 98.7% |
| EBITDA Margin | -4.5% |
| Operating Margin | -11.3% |
| Net Margin | -4.2% |
Returns
-9.3%ROE
-3.3%ROA
Balance Sheet Health
Debt / Equity0.11x
Current Ratio4.04x
Net Debt-$820.6Mnet cash position
Cash & Equivalents$484.9M
Quality Metrics
Altman Z-Score1.60
Piotroski F-Score3 / 9
FCF Margin-9.6%
Rule of 40-1.7
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $400M
Diluted EPS-$0.37TTMFY2025: $-0.71
Dividend
No dividend
Capital Allocation
R&D Spend$284.5M
Capex Intensity1.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| KIMMTRAK (tebentafusp) | $400M | +29.0% | View detailsExpect continued, albeit moderated, growth in 2026 as market penetration matures. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.